Philip J. Saylor, MD
- Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ.Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).J Clin Oncol. 2014 Apr 10;32(11):1143-50.
- Saylor PJ.Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.Asian J. Androl. 2014 Jan 7.
- Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR.A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.Clin Cancer Res. 2013 Apr 3.
- Saylor PJ.Prostate cancer: The androgen receptor remains front and centre.Nat Rev Clin Oncol. 2013 Mar;10(3):126-8.
- Saylor PJ, Smith MR, O'Malley AJ, Keating NL.Androgen-deprivation Therapy and Risk for Biliary Disease in Men with Prostate Cancer.Eur Urol. 2013 Feb 12.
- Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K.New and emerging therapies for bone metastases in genitourinary cancers.Eur Urol. 2013 Feb;63(2):309-20.
- Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD.Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer.J Nucl Med. 2012 Nov;53(11):1670-5.
- Saylor PJ, Karoly ED, Smith MR.Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer.Clin Cancer Res. 2012 Jul 1;18(13):3677-85.
- Lee RJ, Saylor PJ, Smith MR.Contemporary therapeutic approaches targeting bone complications in prostate cancer.Clin Genitourin Cancer. 2010 Dec 1;8(1):29-36.
- Lee RJ, Saylor PJ, Smith MR.Treatment and prevention of bone complications from prostate cancer.Bone. 2011 Jan 1;48(1):88-95.
- Saylor PJ.Re: Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy. Editorial comment.J Urol. 2010 Sep;184(3):923; author reply 924.
- Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR.Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.J Urol. 2010 Jun;183(6):2200-5.
- Saylor PJ, Fogerty AE.Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation?.Lancet Oncol. 2010 May;11(5):406-7.
- Saylor PJ, Smith MR.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.J Natl Compr Canc Netw. 2010 Feb;8(2):211-23.
- Saylor PJ, Keating NL, Smith MR.Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.J Gen Intern Med. 2009 Nov;24 Suppl 2:S389-94. Review.
- Saylor PJ, Smith MR.Prostate cancer: How can we improve the health of men who receive ADT?.Nat Rev Urol. 2009 Oct;6(10):529-31.
- Saylor PJ, Michaelson MD.New treatments for renal cell carcinoma: targeted therapies.J Natl Compr Canc Netw. 2009 Jun;7(6):645-56. Review.
- Saylor PJ,Smith MR.Metabolic complications of androgen deprivation therapy for prostate cancer.J Urol. 2009 May;181(5):1998-2006; discussion 2007-8. Review.
- Saylor PJ, Reid TR.Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.J Clin Oncol. 2007 Aug 10;25(23):3544-6.